Development of a marketable adjuvant candidate for vaccine applications

Introduction

ADJUVACCINE seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the scalable production of identified optimized saponin adjuvants for improved cost-effective vaccines.

Development of Adjuvant Leads

We have developed in the laboratory potent, safe, stable, and streamlined adjuvant leads that surpass the QS-21 natural product adjuvant, leading to patent applications and the interest of Pharma.

Project Objectives

In this PoC project, we aim to exploit our synthetic saponin technology to produce adjuvant/vaccine candidates at scale that outperform existing products more cost-effectively. This approach lowers the risk profile of the commercialization potential while also achieving valorization outcomes for market entry.

The main objectives are:

1. Demonstrate our synthetic technology platform for the gram-scale production and selection of a candidate adjuvant lead.
2. Implement valorization opportunities and verify the potential of spin-off creation by establishing an optimal IPR and public/private funding roadmap plan.

Innovation Potential

The breakthrough innovation potential of ADJUVACCINE lies in the exploitation of this adjuvant platform for large-scale production and selection of the best candidate lead for application in vaccines against various diseases, improving the available vaccine solutions.

Unique Attributes

The high purity and excellent chemical control of our synthetic technology versus the heterogeneous natural product adjuvants, as well as its streamlined, scalable nature and low-cost profile, are unique attributes of our platform that will be valorized herein. This makes it a potentially superior alternative to existing vaccine models with less structural definition and costlier timelines.

Conclusion

The goal is to demonstrate the scalability of our innovative adjuvant technology and select an optimal adjuvant candidate in advanced preclinical settings for entering the vaccine market via spin-off formation following proper IPR strategy implementation and attraction of key investors/partners.